Salvinorin A Regulates Dopamine Transporter Function Via A Kappa Opioid Receptor and ERK1/2-Dependent Mechanism
dc.contributor.author | Kivell, Bronwyn | |
dc.contributor.author | Uzelac, Zeljko | |
dc.contributor.author | Sundaramurthy, Santhanalakshmi | |
dc.contributor.author | Rajamanickam, Jeyaganesh | |
dc.contributor.author | Ewald, Amy | |
dc.contributor.author | Chefer, Vladimir | |
dc.contributor.author | Jaligam, Vanaja | |
dc.contributor.author | Bolan, Elizabeth | |
dc.contributor.author | Simonson, Bridget | |
dc.contributor.author | Annamalai, Balasubramaniam | |
dc.contributor.author | Mannangatti, Padmanabhan | |
dc.contributor.author | Prisinzano, Thomas E. | |
dc.contributor.author | Gomes, Ivone | |
dc.contributor.author | Jayanthi, Lankupalle D. | |
dc.contributor.author | Sitte, Harald H. | |
dc.contributor.author | Ramamoorthy, Sammanda | |
dc.contributor.author | Shippenberg, Toni S. | |
dc.date.accessioned | 2017-02-16T19:22:32Z | |
dc.date.available | 2017-02-16T19:22:32Z | |
dc.date.issued | 2014-11 | |
dc.identifier.citation | Kivell, B., Uzelac, Z., Sundaramurthy, S., Rajamanickam, J., Ewald, A., Chefer, V., … Shippenberg, T. S. (2014). Salvinorin A Regulates Dopamine Transporter Function Via A Kappa Opioid Receptor and ERK1/2-Dependent Mechanism. Neuropharmacology, 86, 228–240. http://doi.org/10.1016/j.neuropharm.2014.07.016 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23191 | |
dc.description.abstract | Salvinorin A (SalA), a selective κ-opioid receptor (KOR) agonist, produces dysphoria and pro-depressant like effects. These actions have been attributed to inhibition of striatal dopamine release. The dopamine transporter (DAT) regulates dopamine transmission via uptake of released neurotransmitter. KORs are apposed to DAT in dopamine nerve terminals suggesting an additional target by which SalA modulates dopamine transmission. SalA produced a concentration-dependent, nor-binaltorphimine (BNI)- and pertussis toxin-sensitive increase of ASP+ accumulation in EM4 cells coexpressing myc-KOR and YFP-DAT, using live cell imaging and the fluorescent monoamine transporter substrate, trans 4-(4-(dimethylamino)-styryl)-N-methylpyridinium) (ASP+). Other KOR agonists also increased DAT activity that was abolished by BNI pretreatment. While SalA increased DAT activity, SalA treatment decreased serotonin transporter (SERT) activity and had no effect on norepinephrine transporter (NET) activity. In striatum, SalA increased the Vmax for DAT mediated DA transport and DAT surface expression. SalA up-regulation of DAT function is mediated by KOR activation and the KOR-linked extracellular signal regulated kinase-½ (ERK1/2) pathway. Co-immunoprecipitation and BRET studies revealed that DAT and KOR exist in a complex. In live cells, DAT and KOR exhibited robust FRET signals under basal conditions. SalA exposure caused a rapid and significant increase of the FRET signal. This suggests that the formation of KOR and DAT complexes is promoted in response to KOR activation. Together, these data suggest that enhanced DA transport and decreased DA release resulting in decreased dopamine signaling may contribute to the dysphoric and pro-depressant like effects of SalA and other KOR agonists. | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License 3.0 (CC BY-NC-ND 3.0 US), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Kappa opioid receptor | en_US |
dc.subject | Dysphoric | en_US |
dc.subject | Pro-depressant | en_US |
dc.subject | Dopamine transporter | en_US |
dc.subject | Serotonin transporter | en_US |
dc.subject | Trafficking | en_US |
dc.subject | Salvinorin A | en_US |
dc.title | Salvinorin A Regulates Dopamine Transporter Function Via A Kappa Opioid Receptor and ERK1/2-Dependent Mechanism | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Prisinzano, Thomas E. | |
kusw.kudepartment | Medicinal Chemistry | en_US |
dc.identifier.doi | 10.1016/j.neuropharm.2014.07.016 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License 3.0 (CC BY-NC-ND 3.0 US), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.